Colorectal Cancer

 

Cetuximab and/or Bevacizumab + Combination Chemotherapy For Metastatic Colorectal Cancer (CTSU C80405)
A Phase III Trial of Irinotecan(Camptosar)/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab (Avastin), or Cetuximab (C225) (Erbitux), or With The Combination of Bevacizumab, or Cetuximab For Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Investigator: Fred Appelbaum, MD;   Conditions: Colon Cancer, Rectal Cancer, Colorectal Cancer;    Status: Recruiting;   Study ID: NCT00265850

SIRT + FOLFOX for Liver Metastases from Colorectal Cancer
Randomised Comparative Study Of Folfox6m Plus SIR-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma

Investigator: Samuel Whiting, MD, PhD;   Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases;    Status: Recruiting;   Study ID: NCT00724503

A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer (SWOG 0713)
Oxaliplatin (Eloxatin), Capecitabine (Xeloda), Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Investigator: Fred Appelbaum, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT00686166

FOLFIRI + Ramucirumab for Metastatic Colorectal Cancer (UW10034)
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab (Avastin), Oxaliplatin, and a Fluoropyrimidine

Investigator: Veena Shankaran;   Conditions: Colon Cancer; Gastrointestinal Cancer; Rectal Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01183780

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (NSABP P-5)
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Investigator: Tanya Wahl, MD;   Conditions: Colon Cancer;    Status: Recruiting;   Study ID: NCT01011478

Octreotide and Interferon Alfa-2b or Bevacizumab for Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (SWOG 0518)
Phase III Prospective Randomized Comparison of Depot Octreotide (Sandostatin) plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (Avastin) (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Investigator: Fred Appelbaum, MD;   Conditions: Neuroendocrine Carcinoma, Gastrointestinal Cancer;    Status: Recruiting;   Study ID: NCT00569127

PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors

Investigator: Heidi J. Gray, MD;   Conditions: Advanced Solid Tumors;    Status: Not Recruiting;   Study ID: NCT01063816

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma;    Status: Recruiting;   Study ID: NCT00729664